- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04054401
SynerFuse Spinal Fusion and Neuromodulation Proof of Concept Study
March 29, 2023 updated by: SynerFuse, Inc
The purpose of the study is to evaluate the safety and tolerability of DRG stimulation when placing a neurostimulator during the same procedure as implantation of spinal fixation with or without interbody cage systems in patients with chronic back and/or leg pain requiring single level spinal fusion.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gabi Molnar
- Phone Number: 612-217-2914
- Email: Gabi@SynerFuse.com
Study Locations
-
-
Indiana
-
Mishawaka, Indiana, United States, 46544
- Recruiting
- South Bend Orthopaedics
-
Contact:
- Derek Yocum, PhD
- Phone Number: 574-247-9441
- Email: ClinicalResearch@sbortho.com
-
Principal Investigator:
- Deepak Reddy, MD
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Kristin Frenn
- Email: fren0108@umn.edu
-
Principal Investigator:
- Michael Park, MD, PhD
-
Sub-Investigator:
- Rohan Lall, MD
-
Sub-Investigator:
- Jonathan Sembrano, MD
-
Sub-Investigator:
- Matthew Hunt, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Indicated for a single level or two level adjacent spinal fusion having back pain and radiculopathy
- Have been diagnosed with chronic, intractable pain of the lower back and/or leg refractory to conservative therapy for at least 3 of months
- At least 6 months since last surgical procedure on the spine
- Be 21 years of age or older at the time of enrollment
- Be willing and capable of giving informed consent
- Be willing and able to comply with study-related requirements
Exclusion Criteria:
- Any prior spinal fusion at index or adjacent level
- Pregnant
- Have a life expectancy of less than 1 year
- Be concomitantly participating in another clinical study
- Be involved in an injury claim under current litigation
- Baseline narcotic use of ≥ 100 MME per day
- Significant untreated addiction to dependency producing medications
- Current active implantable medical device
- Cancer
- Have osteoporosis
- Active infection
- Allergies to system components
- AGE > 80
- Expected need to undergo MRI imaging in the future
- Other significant comorbidities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DRG Neurostimulation with Spinal Fusion
|
Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Safety Endpoint: Characterization of device-related adverse events
Time Frame: Surgery through 12 months post-op
|
Surgery through 12 months post-op
|
|
Primary Effectiveness Endpoint: Change in back and leg pain Visual Analog Score (VAS) scores
Time Frame: Baseline to 3 months post-op
|
VAS scores range from 0 (no pain) to 100 (pain is as bad as it could possibly be).
Decreases in scores indicate reductions in pain.
|
Baseline to 3 months post-op
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in neurological status
Time Frame: Baseline to 3, 6, and 12 months post-op
|
Change in neurological status measured by the neurological component of the standard physical exam.
|
Baseline to 3, 6, and 12 months post-op
|
Change in disability measured by the Oswestry Disability Index (ODI).
Time Frame: Baseline to 3, 6, and 12 months post-op
|
Each question is scored from 0-5.
The scores from each question are summed, then divided by the maximum number possible, then multiplied by 100 to represent a percentage.
The percentages are broken down into 5 category ranges: 0% to 20%: minimal disability, 21%-40%: moderate disability; 41%-60%: severe disability; 61%-80%: crippled; 80%-100%: bed-bound or exagerating.
|
Baseline to 3, 6, and 12 months post-op
|
Change in quality of life as measured by PROMIS Scale v1.2 - Global Health.
Time Frame: Baseline to 3, 6, and 12 months post-op
|
The is a 10-item patient-reported questionnaire in which the response options are presented as a 5-point rating scale.
The results of the scores are are used to calculate two summary scores: a Global Physical Health score and a Global Mental Health score.
These scores are then standardized to the general population, using the "T-Score."
The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points.
Higher scores indicate a healthier patient.
|
Baseline to 3, 6, and 12 months post-op
|
Change in quality of life as measured by EQ-5D-5L.
Time Frame: Baseline to 3, 6, and 12 months post-op
|
The EQ-5D-5L survey consists of 5 dimensions with the score for each ranging from 1 (no problems) to 5 (unable to do).
For individual dimensions, negative changes (e.g. from 5 to 3) indicate improvement.
The scores on these five dimensions will be presented as a health profile and converted to a single summary index number (utility).
Positive changes in the total score indicate improvement.
|
Baseline to 3, 6, and 12 months post-op
|
Change in use of analgesics over time
Time Frame: Baseline through 12 months post-op
|
Change in use of medications at all follow up visits.
|
Baseline through 12 months post-op
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of device migration
Time Frame: Surgery to 3, 6, and 12 months post-op
|
Amount of device migration as measured by anteroposterior (AP) and lateral x-rays.
|
Surgery to 3, 6, and 12 months post-op
|
Costs and cost-effectiveness of the intervention
Time Frame: Baseline through 12 months post-op
|
The cost effectiveness analysis will report total healthcare-related expenditures reported by patients from baseline to 12 months post-op and 12 month quality-adjusted life-years (QALYs).
Incremental cost per QALY will be estimated and compared to previously published studies.
|
Baseline through 12 months post-op
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2022
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
June 1, 2024
Study Registration Dates
First Submitted
July 30, 2019
First Submitted That Met QC Criteria
August 9, 2019
First Posted (Actual)
August 13, 2019
Study Record Updates
Last Update Posted (Actual)
March 31, 2023
Last Update Submitted That Met QC Criteria
March 29, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- G190045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
There are no plans to make the IPD available to other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Washington University School of MedicineCompletedHip Pain Chronic | Back Pain | Chronic Pain | Knee Pain ChronicUnited States
Clinical Trials on DRG Neurostimulation with Spinal Fusion
-
University of PittsburghWithdrawnSpinal Stenosis | Degenerative Spondylolisthesis
-
Mesoblast, Ltd.CompletedDegenerative Disc Disease | Spinal Stenosis | SpondylolisthesisUnited States
-
Mesoblast, Ltd.CompletedDegenerative Disc Disease | Spinal Stenosis | Degenerative SpondylolisthesisUnited States
-
Olympus Biotech CorporationCompleted
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Pain, Back | Pain, Neuropathic | Intractable PainUnited States
-
Mesoblast, Ltd.WithdrawnDegenerative Disc Disease | Spinal Stenosis | Degenerative SpondylolisthesisUnited States
-
University Health Network, TorontoActive, not recruitingSpinal Stenosis | SpondylolisthesisCanada
-
Mesoblast, Ltd.CompletedSpinal Stenosis | Cervical Degenerative Disc Disease | Degenerative SpondylolisthesisUnited States
-
Sewon Cellontech Co., Ltd.UnknownSpinal Fusion Acquired | Fusion of Spine (Disease)Korea, Republic of
-
Turku University HospitalHelsinki University Central Hospital; Oxford University HospitalNot yet recruitingAdolescent Idiopathic Scoliosis